## Evaluating the safety profile of defibrotide in sickle cell disease: an *in vitro* study

## **Authors**

Laura Bencheikh,¹ Meghan Perkins,¹ Kim Anh Nguyen,²,³ Clara Noizat,⁴ Anoosha Habibi,⁴ Marie Cambot¹ and Pablo Bartolucci²,⁴

<sup>1</sup>Innovhem; <sup>2</sup>Université Paris-Est Créteil, INSERM U955, IMRB, Laboratory of Excellence LABEX; <sup>3</sup>Etablissement Français du Sang and <sup>4</sup>Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital-UPEC, AP-HP, Créteil, France

Correspondence:

P. BARTOLUCCI - Pablo.bartolucci@aphp.fr

https://doi.org/10.3324/haematol.2025.287447

Received: January 29, 2025. Accepted: April 28, 2025. Early view: May 8, 2025.

©2025 Ferrata Storti Foundation
Published under a CC BY-NC license

## Supplemental Figure legend:

Figure S1. Defibrotide does not modify the release of soluble E-selectin, P-selectin, ICAM-1, VCAM-1, IL-1β and vWF by endothelial cells. After 16-40 hours of culture under flow conditions (using KIMA pumps, Cellix) in μ-slides (IBIDI) coated with fibronectin, human umbilical vein endothelial cells (HUVEC) were perfused for 4 hours with culture medium containing 20 ng/mL TNF-α, with or without 300 μg/mL Defibrotide (DF) or 10% hemolysate +/- 300 μg/mL DF. (A) Soluble E-selectin, (B) P-selectin, (C) ICAM-1, (D) VCAM-1, (E) IL-1β, and (F) von Willebrand factor (vWF) concentrations were measured by Luminex (MagPix, Thermofisher) and by ELISA for vWF (Thermofisher) in HUVEC supernatant collected after the 4-hour treatment with TNF-α or hemolysate (samples treated with DF in grey). Data are presented as median with interquartile range and were analyzed using the Wilcoxon test (comparisons to the 0 μg/mL condition) on GraphPad Prism 10. All p-values were > 0.05.

